- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01562431
The Signal-Trial: Evaluation of a Screening Tool for Psychosocial Problems in Cancer Genetics
Background
An important part of individuals undergoing genetic counseling and/or testing for cancer experience psychosocial problems and worries during or after this process. Approximately 20% of these individuals experience serious problems, such as fear for cancer in themselves or their relatives, family communication problems, unresolved grief, problems in coping with the DNA-test-results, difficulties in choices with regard to DNA-testing, preventive surgeries, and concerns about insurance or work. Research shows that these problems are frequently undetected by the counselors. Within the limited available time of a counseling session, a lot of information should be given to the counselee. This information is mostly biomedical and provider driven. Therefore psychosocial issues can be underexposed. The use of a brief questionnaire, completed by the counselee prior to the counseling session, can serve as a tool for the counselor to screen and address the relevant psychosocial issues in a systematic manner. Therefore, in 2009-2010 the investigators have developed and validated the 'Signal-checklist' to identify relevant psychosocial problems frequently encountered in the cancer-genetics setting, and need for extra psychosocial services. This 'Signal-checklist' can serve as a tool in screening systematically for psychosocial issues, addressing these issues and directing appropriate referrals to extra psychosocial services. The Signal-Trial will be performed to evaluate the use and effectiveness of the checklist.
Aim
The aim of the trial is to evaluate the implementation of a short, self-developed cancer-genetics checklist; the 'Signal-checklist', as an aid in 1) facilitating communication on psychosocial issues during the genetic counseling session, 2) increasing counselors awareness of psychosocial problems of the counselee, and 3) improving the management of these psychosocial problems during and after the process of genetic counselling.
Method
This study is a collaboration between the family cancer clinics of the NKI-AVL and the UMCU. Individuals requesting genetic counseling for the high incidence of cancer in their family are invited to participate in the trial. Participants will be asked to complete the 'Signal checklist' prior to their counseling visit. Participants (N=264) will be randomly assigned to one of the two study arms. The intervention group will receive feed-back on the 'Signal-checklist', whereas the control group will not receive feed-back. Three weeks after the DNA-test disclosure session, participants will be asked to complete again the 'Signal-checklist' followed by a telephone call by their counselor. Again, the results of the 'Signal-checklist' will be available to the counselor for participants in the intervention group, but not for the control group. Both the genetic counseling session and telephone call will be audio taped. Furthermore, all participants will be asked to complete three questionnaires on the Internet (or by mail, if preferred); 1) before randomization (3 weeks prior to the counseling session), 2) three weeks after the counseling session, and 3) four months after the potential DNA-test result disclosure. These questionnaires include items on communication during genetic counseling, the need for professional psychosocial support, cancer worries, satisfaction with received care, and experiences with the use of the 'Signal-checklist'. The audio-tapes and completed questionnaires will be used to measure psychosocial problems of the counselees, the awareness of the counselors of these problems, and the management of these problems. Secondary analysis will be conducted to assess the need for extra psychosocial services, satisfaction with genetic counseling, feasibility of implementing the 'Signal-checklist' and decreasing psychosocial problems over time.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Noord-Holland
-
Amsterdam, Noord-Holland, Netherlands, 1066 CX
- Netherlands Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years of age or older
- Sufficient command of the Dutch language to be able to complete questionnaires
- Attendees of a second visit at the family cancer clinic because of increased risk of developing cancer due to a hereditary predisposition
Exclusion Criteria:
- Those who do not fulfill the inclusion criteria
Study Plan
How is the study designed?
Design Details
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
OTHER: Control
Participants complete the Signal-checklist BUT counselors do not obtain the results of the checklist
|
Counselors will receive the results of the completed Signal-checklist completed by participants in the intervention group
|
|
OTHER: Intervention
Participants complete the Signal-checklist AND the counselor will get the results of the questionnaire
|
Counselors will receive the results of the completed Signal-checklist completed by participants in the intervention group
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Communication on psychosocial issues at the counseling session
Time Frame: 3 weeks after randomization
|
The counseling session at the clinic will be audio taped, and content analyzed to evaluate counselor- counselee communication.
A study-specific checklist will be used to rate whether psychosocial problems are discussed during the counseling session.
|
3 weeks after randomization
|
|
Counselors awareness of psychosocial problems of the counselee at the counseling session
Time Frame: 3 weeks after randomization
|
After each consult with a counselee, the counselor will have to complete a short form regarding their awareness of psychosocial problems of the counselee.
The level of agreement between the counselor and the counselee will be assessed
|
3 weeks after randomization
|
|
Management of these psychosocial problems of the counselee during the counseling session
Time Frame: 3 weeks after randomization
|
Management of the psychosocial problems will be measured using the audio-taped sessions.
The study-specific checklist will be used to rate whether problems are being counseled during the session and/or counselees are being referred to extra psychosocial services.
|
3 weeks after randomization
|
|
Communication on psychosocial issues at telephone follow-up
Time Frame: up to 4 months after randomization
|
The telephone follow-up will be audio taped, and content analyzed to evaluate counselor- counselee communication.
A study-specific checklist will be used to rate whether psychosocial problems are discussed during the counseling session.
|
up to 4 months after randomization
|
|
Counselors awareness of psychosocial problems of the counselee at follow-up
Time Frame: Up to 4 months after randomization)
|
After each consult with a counselee, the counselor will have to complete a short form regarding their awareness of psychosocial problems of the counselee.
The level of agreement between the counselor and the counselee will be assessed
|
Up to 4 months after randomization)
|
|
Management of these psychosocial problems of the counselee at follow-up
Time Frame: Up to 4 months after randomization
|
Management of the psychosocial problems will be measured using the audio-taped sessions.
The study-specific checklist will be used to rate whether problems are being counseled during the session and/or counselees are being referred to extra psychosocial services.
|
Up to 4 months after randomization
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Initiation of discussed problems
Time Frame: Counseling session (3 weeks after randomization) and telephone follow-up (up to 4 months after randomization)
|
Counseling session (3 weeks after randomization) and telephone follow-up (up to 4 months after randomization)
|
|
Time spent on psychosocial problems
Time Frame: Counseling session (3 weeks after randomization) and telephone follow-up (up to 4 months after randomization)
|
Counseling session (3 weeks after randomization) and telephone follow-up (up to 4 months after randomization)
|
|
Counselee and counselor's level of satisfaction
Time Frame: 4 weeks after counseling session (7 weeks after randomization) and 4 months after telephone follow-up (up to 8 months after randomization)
|
4 weeks after counseling session (7 weeks after randomization) and 4 months after telephone follow-up (up to 8 months after randomization)
|
|
Levels of counselee cancer worries
Time Frame: Before randomization (Baseline, 1 week before randomization), 4 weeks after counseling session (7 weeks after randomization) and 4 months after telephone follow-up (up to 8 months after randomization)
|
Before randomization (Baseline, 1 week before randomization), 4 weeks after counseling session (7 weeks after randomization) and 4 months after telephone follow-up (up to 8 months after randomization)
|
|
Number of psychosocial problems
Time Frame: Counseling session (3 weeks after randomization) and telephone follow-up (up to 4 months after randomization) and 4 months after telephone follow-up (up to 8 months after randomization)
|
Counseling session (3 weeks after randomization) and telephone follow-up (up to 4 months after randomization) and 4 months after telephone follow-up (up to 8 months after randomization)
|
|
Counselee and counselor evaluation of the intervention/ feasibility of the implementation of the intervention
Time Frame: 4 weeks after counseling session (7 weeks after randomization) and 4 months after telephone follow-up (up to 8 months after randomization)
|
4 weeks after counseling session (7 weeks after randomization) and 4 months after telephone follow-up (up to 8 months after randomization)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: E.M.A. Bleiker, PHd., The Netherlands Cancer Institute
- Principal Investigator: N.K. Aaronson, PHd., The Netherlands Cancer Institute
- Principal Investigator: D.E.E. Hahn, MSc., The Netherlands Cancer Institute
- Principal Investigator: I Kluijt, MSc., The Netherlands Cancer Institute
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- P11SIG
- 2008-4016 (OTHER_GRANT: Dutch Cancer Society)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer Genetics
-
National Human Genome Research Institute (NHGRI)Johns Hopkins Bloomberg School of Public HealthCompleted
-
National Human Genome Research Institute (NHGRI)CompletedData Analysis | Cancer GeneticsUnited States
-
Texas A&M UniversityRecruitingDisease | Cancer | Genetics | Diet | Lifestyle FactorsUnited States
-
National Cancer Institute (NCI)Terminated
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedGeneticsUnited States
-
Universidad Francisco de VitoriaSofía Laguarta Val; Alberto Melián OrtizCompletedEffectiveness of Muscular Work and Genetic Variants in Strength Gain of Ischiofemoral and QuadricepsGenetics | Muscle Strength
-
University of Eastern FinlandCompletedGenetics | Fatty AcidsFinland
-
National Human Genome Research Institute (NHGRI)Completed
-
HelicalCodeMDJohnson & Johnson; 23andMe, Inc.Completed
-
Institut National de la Santé Et de la Recherche...Commissariat A L'energie AtomiqueActive, not recruiting
Clinical Trials on Feed-back
-
Karolinska InstitutetCompletedImproved Prevention of Stroke in Primary Care in Stockholm, Sweden (Förbättrad Prevention av Stroke)Ischemic Stroke | Atrial Fibrillation | Hemorrhagic Stroke | TIASweden
-
University of OxfordNot yet recruiting
-
Collège National des Généralistes EnseignantsAssistance Publique - Hôpitaux de Paris; Institut National de la Santé Et de... and other collaboratorsCompletedHigh Risk Hypertensive PatientsFrance
-
Barts & The London NHS TrustBristol Royal Infirmary; Institute of Child HealthCompleted
-
Region SkaneLund University; Helsinki University Central Hospital; The George Institute for... and other collaboratorsRecruitingCognitive Impairment | Caregiver Burden | Hypoxia, Brain | Cardiac Arrest With Successful ResuscitationSweden, Finland, United Kingdom, Switzerland, New Zealand, Belgium, Australia, Germany, Norway, Luxembourg
-
Hiroshima Kyoritsu HospitalCompleted
-
Nutricia UK LtdUniversity College London Hospitals; Nottingham University Hospitals NHS Trust and other collaboratorsRecruitingEnteral Feeds | Enteral Nutrition (Food for Special Medical Purposes)United Kingdom
-
Florida International UniversityAcademy of Nutrition and DieteticsCompletedObesity, ChildhoodUnited States
-
Boston Children's HospitalRecruiting
-
University of North Carolina, Chapel HillAmerican Heart Association; Community ServingsCompleted